A three-component composition for use in the treatment of preeclampsia and related disorders wherein a first component comprises a bimodal synthetic carbon particle mixture; a second component comprises a resin bead with at least one affinity ligand directed toward syncytiotrophoblast-derived factor sEndoglin and a third component comprises a resin bead with at least one affinity ligand directed toward syncytiotrophoblast-derived factor soluble Fms-like tyrosine kinase-1.